Skip to main content

What Johnson & Johnson's Quarter ended Sep 27, 2026 10-Q says: 8 signals

Johnson & Johnson filed its latest 10-Q with the SEC on Oct 21, 2026. It discusses acquisition completed, digital transformation and goodwill impairment.

Public (JNJ)Pharmaceutical Manufacturing10,000+ employeesjnj.comLinkedIn

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.
Filed
Oct 21, 2026
Period
Quarter ended Sep 27, 2026
Filings
3
Signals
20

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

10-Q · latest 10

What Johnson & Johnson's 10-Q filings say

  1. 10-Q · Quarter ended Sep 27, 2026

    Filed · 8 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 28, 2026

    Filed · 6 signals

    SEC EDGAR

Earlier 10-Q filings

  • 10-Q · Quarter ended Mar 29, 2026Filed · 6 signalsSEC EDGAR

Showing 10 of 20 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Johnson & Johnson earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Worldwide sales rise 6% to $25.4B, exceeding consensusWorldwide sales reached $25.4 billion in Q3 2026, representing operational growth of 6.0%. Growth was driven by 9.1% expansion in the U.S. and 1.8% outside the U.S., placing the company on track to surpass $100 billion in full-year revenue for the first time.
Raised 2026 operational sales guidance to $100.7B midpointFull-year 2026 operational sales guidance was raised to 6.7%-7.1%, representing $100.7 billion at the midpoint (6.9% growth). Reported sales growth is projected at 7.2%-7.6% ($101.2 billion midpoint), with adjusted operational EPS guidance raised to $10.95-$11.05.
Completed $1B acquisition of Firefly Bio for oncologyThe company completed the acquisition of Firefly Bio, deploying $1 billion to acquire its degrader antibody conjugate platform targeting difficult-to-treat cancer drivers such as KRAS. The transaction impacted Q3 adjusted and GAAP earnings by approximately $1 billion in acquired IPR&D.
Innovative Medicine sales grow 7.9% to $16.8BInnovative Medicine posted worldwide sales of $16.8 billion, expanding 7.9% operationally with U.S. growth of 11.1%. Performance was led by oncology up approximately 17%, including DARZALEX growing 15.6% and TREMFYA jumping 68.2% across immunology indications.
Received FDA de novo authorization for OTTAVA robotic systemThe U.S. FDA granted de novo clearance for OTTAVA, a soft-tissue robotic surgery system connected to the Polyphonic digital ecosystem. The company secured its first commercial customer and initiated an investigational device exemption trial in inguinal hernia repair.
VARIPULSE Pro approved in Japan, driving European expansionVARIPULSE Pro received regulatory approval in Japan following strong commercial traction and double-digit growth in Europe. The company is preparing for an impending U.S. commercial launch by the end of 2026 for the pulsed field ablation catheter.

Signal API · MCP

Track Johnson & Johnson with the Signal API

One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Johnson & Johnson 10-Q

When did Johnson & Johnson file its latest 10-Q?
Johnson & Johnson filed its latest 10-Q (Quarter ended Sep 27, 2026) on Oct 21, 2026. The one before it was filed on Jul 23, 2026.
What did Johnson & Johnson disclose in its latest 10-Q?
From the filing dated Oct 21, 2026: Recorded $5.5 billion charge for proposed talc ovarian litigation resolution
What did Johnson & Johnson say on its recent earnings calls?
Q3 FY2026: Worldwide sales rise 6% to $25.4B, exceeding consensus (dated Oct 13, 2026).
Where can I read Johnson & Johnson's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/jnj-20260927.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →